Bausch Health Companies | VRX - Cash And Equivalent


Bausch Health Companies reported $1.83B in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Amgen USD 13.99B 1.95B Jun/2026
ANI Pharmaceuticals USD 360.21M 49.04M Jun/2026
Aurora Cannabis CAD 64.69M 8.33M Mar/2026
Bausch Health Companies USD 1.83B 526M Jun/2026
Biogen USD 1.28B 2.1B Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Canopy Growth CAD 364.68M 6.64M Mar/2026
Corcept Therapeutics USD 111.04M 2.3M Jun/2026
Danaher USD 4.35B 1.35B Jun/2026
Drreddys Laboratories INR 15.37B 3.29B Mar/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
Gilead Sciences USD 7.63B 64M Mar/2026
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Pacira USD 205.88M 61.57M Jun/2026
Perrigo USD 357.2M 174.4M Mar/2026
Phibro Animal Health USD 61.42M 6.49M Jun/2026
Prestige Brands USD 89.13M 25.26M Jun/2026
Supernus Pharmaceuticals USD 179.95M 4.92M Jun/2026
Vertex Pharmaceuticals USD 7.85B 605.7M Jun/2026
Zoetis USD 1.48B 465M Jun/2026